Combivent® HFA-propelled Compared to CFC-propelled Metered Dose Inhaler in Patients With COPD (Chronic Obstructive Pulmonary Disease)
Primary Purpose
Pulmonary Disease, Chronic Obstructive
Status
Terminated
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
Combivent® HFA inhalation aerosol
Combivent® CFC inhalation aerosol
Sponsored by
About this trial
This is an interventional treatment trial for Pulmonary Disease, Chronic Obstructive
Eligibility Criteria
Inclusion Criteria:
- Male or female patients 40 years of age or older
- A diagnosis of COPD as defined by American Thoracic Society (ATS) criteria. Patients must have relatively stable, moderate to severe airway obstruction with a baseline FEV 1 <=65% of predicted normal and FEV1/FVC >=70%.
- A smoking history of more than ten pack-years. A pack-year is defined as the equivalent of smoking one pack of 20 cigarettes per day for a year
- Able to perform technical satisfactory pulmonary function test
- Able to be trained in the proper use of a MDI
- Having signed an informed consent from prior to participation in the trial
- Affiliation to the French social security system or beneficiary of such a system
Exclusion Criteria:
- Significant disease other than COPD. A significant disease is defined as a disease which in the opinion of the investigator may either put the patient at risk because of participation in the study or a disease which may influence the results of the study or the patient's ability to participate in the study
- Clinical relevant abnormal baseline hematology, blood chemistry or urinalysis. If the abnormality defines a disease listed as an exclusion criterion, the patient is excluded
- Serum glutamic oxaloacetic transaminase (SGOT) >80 IU/L; serum glutamic pyruvic transaminase (SGPT) >80IU/L, bilirubin >2.0mg/dL or creatinine >2.0mg/dL
- Serum potassium level above or below the normal range
- Total blood eosinophil count >=600/mm³
- Recent history (i.e., one year or less) of myocardial infarction
- Recent history (i.e., three years or less) of heart failure or any cardiac arrhythmia requiring drug therapy
- History of cancer, other than treated basal cell carcinoma, within the last five years
- History of life-threatening pulmonary obstruction, or a history of cystic fibrosis or bronchiectasis
- History of thoracotomy with pulmonary resection. History or a thoracotomy for other reasons should be evaluated as per exclusion criteria no. 1
- History of asthma, allergic rhinitis or atopy
- History of or active alcohol or drug abuse
- Known active tuberculosis
- Upper respiratory tract infection or COPD exacerbation in the six weeks prior to screening visit or between the screening visit and visit 2
- Known symptomatic prostatic hypertrophy or bladder neck obstruction
- Known narrow-angle glaucoma
- Current significant psychiatric disorders
- Regular use of daytime oxygen therapy
- Use of beta-blocker medications, mono-amine oxidase inhibitors or tricyclic antidepressants
- Use of cromolyn sodium or nedocromil sodium
- Use of antihistamines.
- Use of oral corticosteroid medication at unstable doses (i.e., less than six weeks on a stable dose before screening visit or a change between the screening visit and visit2) or at a dose in excess of the equivalent of 10 mg of prednisone per day or 20mg every other day
- Use of oral beta-adrenergics or long-acting beta-adrenergics such as salmeterol (Serevent®) and formoterol in the two weeks prior to the screening visit or between the screening visit and visit 2
- Changes in the therapeutic plan within the last six weeks prior to the screening visit or between the screening visit and visit 2, excluding changes from long acting or oral beta-adrenergics to short acting inhaled beta-adrenergics for purposes of this trial
- Pregnant or nursing women or women of childbearing potential not using a medically approved means of contraception
- Known hypersensitivity to anti-cholinergic or beta-agonist drugs or any other component of either Combivent® formulations
- Use of an investigational drug within one month or six half lives prior to the screening visit
- Previous participation in this study
- Patient deprived of their freedom by a judicial or administrative decision
- Patient leaving in medical or social establishments
- Patient hospitalized for mental disorder without his (her) consent
- Patient under guardianship
- Patient in emergency situations
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Combivent® HFA
Combivent® CFC
Arm Description
Outcomes
Primary Outcome Measures
Number of patients with clinically significant changes in electrocardiogram (ECG) parameters (ventricular rate, PQ, QRS, QT and QTc intervals)
Number of patients with clinically significant changes in vital signs (blood pressure, puls rate, respiratory rate)
Changes in intra ocular pressure (IOP)
Changes in serum potassium levels
Changes in serum glucose levels
Number of patients with clinically significant changes from baseline in clinical laboratory evaluations
Number of patients with adverse events including paradoxical bronchospasm
Number of patients with clinically significant changes from baseline in physical examination
Secondary Outcome Measures
Change in FEV1 (forced expiratory volume in one second)
Change in FVC (forced vital capacity)
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02182869
Brief Title
Combivent® HFA-propelled Compared to CFC-propelled Metered Dose Inhaler in Patients With COPD (Chronic Obstructive Pulmonary Disease)
Official Title
Safety Assessment of Cumulative Dose of Combivent® HFA-propelled Metered Dose Inhaler in Comparison to Combivent® CFC-propelled Metered Dose Inhaler. A Randomised, Double-blind, Active-controlled, Two-way Cross-over Study in COPD Patients
Study Type
Interventional
2. Study Status
Record Verification Date
August 2018
Overall Recruitment Status
Terminated
Study Start Date
April 2001 (undefined)
Primary Completion Date
August 2001 (Actual)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Boehringer Ingelheim
4. Oversight
5. Study Description
Brief Summary
Study to evaluate the safety of combivent delivered in two different formulations (hydrofluoroalkane (HFA) or chlorofluorocarbon (CFC)) from a metered dose inhaler (MDI), using a cumulative dose response model in patients with COPD.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pulmonary Disease, Chronic Obstructive
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Crossover Assignment
Masking
Double
Allocation
Randomized
Enrollment
7 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Combivent® HFA
Arm Type
Experimental
Arm Title
Combivent® CFC
Arm Type
Active Comparator
Intervention Type
Drug
Intervention Name(s)
Combivent® HFA inhalation aerosol
Intervention Type
Drug
Intervention Name(s)
Combivent® CFC inhalation aerosol
Primary Outcome Measure Information:
Title
Number of patients with clinically significant changes in electrocardiogram (ECG) parameters (ventricular rate, PQ, QRS, QT and QTc intervals)
Time Frame
Baseline, up to 8 days after last treatment day
Title
Number of patients with clinically significant changes in vital signs (blood pressure, puls rate, respiratory rate)
Time Frame
Baseline, up to 8 days after last treatment day
Title
Changes in intra ocular pressure (IOP)
Time Frame
Baseline, up to 30 min after last drug administration
Title
Changes in serum potassium levels
Time Frame
Baseline, up to 180 min after last drug administration
Title
Changes in serum glucose levels
Time Frame
Baseline, up to 60 min after last drug administration
Title
Number of patients with clinically significant changes from baseline in clinical laboratory evaluations
Time Frame
Baseline, 8 days after last treatment day
Title
Number of patients with adverse events including paradoxical bronchospasm
Time Frame
Up to 8 days after last treatment day
Title
Number of patients with clinically significant changes from baseline in physical examination
Time Frame
Baseline, 8 days after last treatment day
Secondary Outcome Measure Information:
Title
Change in FEV1 (forced expiratory volume in one second)
Time Frame
Baseline, up to 180 min after last drug administration
Title
Change in FVC (forced vital capacity)
Time Frame
Baseline, up to 180 min after last drug administration
10. Eligibility
Sex
All
Minimum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Male or female patients 40 years of age or older
A diagnosis of COPD as defined by American Thoracic Society (ATS) criteria. Patients must have relatively stable, moderate to severe airway obstruction with a baseline FEV 1 <=65% of predicted normal and FEV1/FVC >=70%.
A smoking history of more than ten pack-years. A pack-year is defined as the equivalent of smoking one pack of 20 cigarettes per day for a year
Able to perform technical satisfactory pulmonary function test
Able to be trained in the proper use of a MDI
Having signed an informed consent from prior to participation in the trial
Affiliation to the French social security system or beneficiary of such a system
Exclusion Criteria:
Significant disease other than COPD. A significant disease is defined as a disease which in the opinion of the investigator may either put the patient at risk because of participation in the study or a disease which may influence the results of the study or the patient's ability to participate in the study
Clinical relevant abnormal baseline hematology, blood chemistry or urinalysis. If the abnormality defines a disease listed as an exclusion criterion, the patient is excluded
Serum glutamic oxaloacetic transaminase (SGOT) >80 IU/L; serum glutamic pyruvic transaminase (SGPT) >80IU/L, bilirubin >2.0mg/dL or creatinine >2.0mg/dL
Serum potassium level above or below the normal range
Total blood eosinophil count >=600/mm³
Recent history (i.e., one year or less) of myocardial infarction
Recent history (i.e., three years or less) of heart failure or any cardiac arrhythmia requiring drug therapy
History of cancer, other than treated basal cell carcinoma, within the last five years
History of life-threatening pulmonary obstruction, or a history of cystic fibrosis or bronchiectasis
History of thoracotomy with pulmonary resection. History or a thoracotomy for other reasons should be evaluated as per exclusion criteria no. 1
History of asthma, allergic rhinitis or atopy
History of or active alcohol or drug abuse
Known active tuberculosis
Upper respiratory tract infection or COPD exacerbation in the six weeks prior to screening visit or between the screening visit and visit 2
Known symptomatic prostatic hypertrophy or bladder neck obstruction
Known narrow-angle glaucoma
Current significant psychiatric disorders
Regular use of daytime oxygen therapy
Use of beta-blocker medications, mono-amine oxidase inhibitors or tricyclic antidepressants
Use of cromolyn sodium or nedocromil sodium
Use of antihistamines.
Use of oral corticosteroid medication at unstable doses (i.e., less than six weeks on a stable dose before screening visit or a change between the screening visit and visit2) or at a dose in excess of the equivalent of 10 mg of prednisone per day or 20mg every other day
Use of oral beta-adrenergics or long-acting beta-adrenergics such as salmeterol (Serevent®) and formoterol in the two weeks prior to the screening visit or between the screening visit and visit 2
Changes in the therapeutic plan within the last six weeks prior to the screening visit or between the screening visit and visit 2, excluding changes from long acting or oral beta-adrenergics to short acting inhaled beta-adrenergics for purposes of this trial
Pregnant or nursing women or women of childbearing potential not using a medically approved means of contraception
Known hypersensitivity to anti-cholinergic or beta-agonist drugs or any other component of either Combivent® formulations
Use of an investigational drug within one month or six half lives prior to the screening visit
Previous participation in this study
Patient deprived of their freedom by a judicial or administrative decision
Patient leaving in medical or social establishments
Patient hospitalized for mental disorder without his (her) consent
Patient under guardianship
Patient in emergency situations
12. IPD Sharing Statement
Links:
URL
http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/1012/1012.43_U03-1212.pdf
Description
Related Info
Learn more about this trial
Combivent® HFA-propelled Compared to CFC-propelled Metered Dose Inhaler in Patients With COPD (Chronic Obstructive Pulmonary Disease)
We'll reach out to this number within 24 hrs